Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well a reduced intensity conditioning regimen after donor
stem cell transplant works in treating patients with multiple myeloma that has come back
(relapsed). Drugs used in chemotherapy, such as cyclophosphamide, tacrolimus, and
mycophenolate mofetil, work in different ways to stop the growth of cancer cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune
system attack the cancer, and may interfere with the ability of tumor cells to grow and
spread. Giving a reduce intensity conditioning regimen consisting of cyclophosphamide,
tacrolimus, mycophenolate mofetil, and daratumumab after donor stem cell transplant may
improve survival and reduce the risk of multiple myeloma coming back.
Phase:
Phase 2
Details
Lead Sponsor:
Ohio State University Comprehensive Cancer Center Srinivas Devarakonda